NFKB1 and acute lymphoblastic leukemia: Altogether, our data corroborate the notion that inhibition of the SERCA pump may be a novel strategy for the treatment of HD-domain-mutant Notch1 T-ALL and that an additional treatment with the NF-κB inhibitor Pt may have further therapeutic benefits.